SCHEMBL686650

SCHEMBL686650

Cc1ccc(OCc2ccccc2)c(OCc2ccccc2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.58
MAPK1 P28482 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
MRGPRX4 Q96LA9 3/20 0.52
PTGER1 P34995 2/20 0.52
PTGER4 P35408 2/20 0.52
PTGER3 P43115 2/20 0.52
PTGER2 P43116 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.50
C5AR1 P21730 1/20 0.50
STAT3 P40763 1/20 0.50
HTT P42858 1/20 0.50
FFAR4 Q5NUL3 1/20 0.49
LIPE Q05469 1/20 0.49
MAOB P27338 1/20 0.48
KDM4E B2RXH2 1/20 0.48
LMNA P02545 1/20 0.48
NPC1 O15118 1/20 0.48
HPGD P15428 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12584881 0.93 KDM4E (0.57) MAPTMAPK1TDP1L3MBTL1MRGPRX4
SCHEMBL171847 0.91 NPC1 (0.58) MAPTMAPK1TDP1L3MBTL1SMN1; SMN2
SCHEMBL827943 0.91 SMPD1 (0.57) MAPTMAPK1TDP1L3MBTL1MRGPRX4
SCHEMBL16433621 0.90 HTR1A (0.50) MAPTMAPK1TDP1L3MBTL1MRGPRX4
SCHEMBL17367260 0.89 L3MBTL1 (0.51) MAPTMAPK1TDP1L3MBTL1MRGPRX4
SCHEMBL7011578 0.88 MAPT (0.50) MAPTMAPK1TDP1L3MBTL1MRGPRX4
SCHEMBL13433963 0.87 L3MBTL1 (0.52) MAPTMAPK1TDP1L3MBTL1PTGER1
SCHEMBL18715976 0.87 L3MBTL1 (0.52) MAPTMAPK1TDP1L3MBTL1PTGER1
SCHEMBL130824 0.87 MRGPRX4 (0.68) MAPTMAPK1TDP1L3MBTL1MRGPRX4
SCHEMBL14228414 0.87 MAPT (0.56) MAPTMAPK1TDP1L3MBTL1MRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3112352-A1 OPIOID RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2017-01-04 EP claimed
EP-1725537-B1 NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-07-13 EP claimed
US-20230190938-A1 NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2023-06-22 US disclosed
EP-2948437-B1 APPROACH FOR SYNTHESIS OF CATECHINS EPIRIUM BIO INC (US) 2021-11-03 EP disclosed
EP-3112352-B1 OPIOID RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-11-21 EP disclosed
EP-3112352-A1 OPIOID RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2017-01-04 EP disclosed
EP-2653465-B1 Opioid receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2016-07-13 EP disclosed
US-9366906-B2 Photoreactive compounds ROLIC AG (CH) 2016-06-14 US disclosed
EP-2573068-B9 Process for preparing intermediates of compounds useful as opioid receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2015-08-26 EP disclosed
EP-2573068-B1 Process for preparing intermediates of compounds useful as opioid receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2014-12-31 EP disclosed
US-20140192305-A1 PHOTOREACTIVE COMPOUNDS ROLIC AG (CH) 2014-07-10 US disclosed
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed
EP-1725537-B1 NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-07-13 EP disclosed
US-7959990-B2 Adjustment of liquid crystals; oligomers, dendrimers, or polymer in solution is applied to support; crosslinking by radiation or polarized light ROLIC AG (CH) 2011-06-14 US disclosed
EP-2298744-A2 Opioid receptor modulators Janssen Pharmaceutica NV (BE) 2011-03-23 EP disclosed
US-20090143312-A1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-06-04 US disclosed
US-20080274304-A1 Functionalized Photoreactive Compounds ROLIC AG (CH) 2008-11-06 US disclosed
US-7388017-B2 Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-06-17 US disclosed
US-7238688-B2 Piperidine compounds SCHERING CORPORATION (US) 2007-07-03 US disclosed
EP-1318140-A1 NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF UGS Mitsubishi Pharma Corporation (JP) 2003-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080274304-A1 Functionalized Photoreactive Compounds PCNA, PIN1, MAP1LC3C MAPT 1166/4885MAPK1 570/4885TDP1 3982/4885
US-20230190938-A1 NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME ATG7, SQSTM1, BECN1 MAPT 288/4885MAPK1 2235/4885TDP1 3803/4885
US-20090143312-A1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE HPN, PRSS1, PRSS3 MAPT 2839/4885MAPK1 3335/4885TDP1 2733/4885
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF MAPT 1368/4885MAPK1 470/4885TDP1 2972/4885
US-20140192305-A1 PHOTOREACTIVE COMPOUNDS PCNA, CRY1, CRY2 MAPT 124/4885MAPK1 3345/4885TDP1 1806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.